Section 9
Chapter 8,820

Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children

Podda, A.; Carapella De Luca, E.; Titone, L.; Casadei, A.M.; Cascio, A.; Bartalini, M.; Volpini, G.; Peppoloni, S.; Marsili, I.; Nencioni, L.

Journal of Pediatrics 123(1): 81-84


ISSN/ISBN: 0022-3476
PMID: 8320630
DOI: 10.1016/s0022-3476(05)81543-4
Accession: 008819221

Download citation:  

We studied the immunogenicity of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin (PT-9K/129G), filamentous haemagglutinin, and a 69-kilodalton protein, pertactin, in 30 children aged 12 to 24 months and in 80 infants aged 2 to 4 months. A significant increase of the neutralizing titer and of the titers against pertussis toxin, filamentous hemagglutinin, and pertactin, as determined by enzyme-linked immunosorbent assay, was achieved after three doses of vaccine in all the children; a significant increase of these antibody titers was obtained in 100%, 96.1%, 93.5%, and 98.7% of the infants, respectively.

PDF emailed within 0-6 h: $19.90